- UroToday Home
- Recent Abstracts
- Urologic Oncology
- Bladder Cancer
Conferences
ANZUP Mini ASM 2021: Molecular Subtypes in MIBC – Moving Toward Better Patient Selection for Treatment
October 19, 2021
ANZUP Mini ASM 2021: Convergence of Machine Learning and Genomics for Precision Cancer Medicine in Genitourinary Cancers and Beyond
October 19, 2021
ANZUP Mini ASM 2021: Cross-Fire Debate: Waiting for Overall Survival Data: We May Wait
October 18, 2021
ANZUP Mini ASM 2021: Cross-Fire Debate: Waiting for Overall Survival Data Is Both Unnecessary and Potentially Harmful
October 18, 2021
ANZUP Mini ASM 2021: Trial Updates: Germ Cell Tumors
October 18, 2021
ANZUP Mini ASM 2021: Trial Updates: Bladder and Penile Cancer
October 18, 2021
ANZUP Mini ASM 2021: Trial Updates: Renal Cell Carcinoma
October 18, 2021
APCCC 2021: What Can Meta-Analyses, Network Meta-Analyses and Subgroup Analyses Tell Us About Treatment Options: Pearls and Pitfalls
October 10, 2021
APCCC 2021: DNA Repair Defect Aberrations – What Are the Differences Between Them and What Is the Impact on Patient Management?
October 10, 2021
APCCC 2021: Contagious Enthusiasm in PSMA-Driven Therapeutics
October 9, 2021
APCCC 2021: Who Needs Germline Testing – Prostate Cancer
October 9, 2021
APCCC 2021: Who Needs Germline Testing for Prostate Cancer and What Should Be Tested?
October 9, 2021
APCCC 2021: Tumor Molecular Testing – Tissue vs Liquid Biopsy
October 9, 2021
